The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetes

The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetes - SGLT2 inhibitor and NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016306

Enrollment

Registered

2015-01-27

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Dapagliflozin 5 mg/day Glimepiride 0.5 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with BMI >_ 25 kg/m2 alchol consumption less than 30 g/day in men and less than 20 g/day in women diagnosed as fatty liver disease by abdominal imaging test

Exclusion criteria

Exclusion criteria: Patients treated with Sulphonyl urea, SGLT2 inhibitor, or insulin Patients with active infection, malignant disease, severe liver or renal dysfunction Pregnant women Patients with dementia or disturbance in consciousness

Design outcomes

Primary

Measure	Time frame
Liver attenuation index	—

Secondary

Measure	Time frame
Visceral fat area	—

Countries

Japan

Contacts

Public ContactRyotaro Bouchi

Tokyo Medical and Dental University Departmet of Molecular Endocrinology and Metabolism

bouchi.mem@tmd.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026